Search / Trial NCT00001166

Gyrate Atrophy of the Choroid and Retina

Launched by NATIONAL EYE INSTITUTE (NEI) · Nov 3, 1999

Apply for Trial

Trial Information

Current as of March 05, 2024

Completed

Keywords

Hyperornithinemia Ornithine Aminotransferase (Oat) Tissue Culture Pyridoxine Hydrochloride Pyridoxal Phosphate Arginine Skin Fibroblast Gyrate Atrophy Autosomal Recessive Retinitis Pigmentosa Bietti's Crystalline Retinopathy Chorioretinal Degeneration

Description

Gyrate atrophy of the choroid and retina (GA) is a rare autosomal recessive chorioretinal degeneration characterized by myopia, cataract, varying degrees of night blindness, and progressive constriction of visual fields associated with chorioretinal atrophy resulting in blindness. The objectives of this protocol are threefold: Document the natural history of gyrate atrophy. Relate the clinical course to the gene defect to explore the genetic heterogeneity inherent in this disease. Assess the clinical course and laboratory findings of the effects of an arginine-deficient diet. The study pop...

Gender

All

Eligibility criteria

  • INCLUSION CRITERIA:
  • Patients must have hyperornithemia and a deficiency of OAT activity to enter the study.

Attachments

readout_NCT00001166_2024-03-05.pdf

4.5 MB

NCT00001166_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0